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Abstract 
 
 
 
 
 
 
 
This work aims to provide for an overview of skin conditions caused and/or triggered by 
different environmental factors and their respective treatments. Through examining those 
disorders and different options of treatment currently at disposal, one will obtain a thorough 
insight into the respective field of Dermatology. The work also analyzes different factors 
causing the conditions, namely, UV radiation, extreme temperatures and exposure to toxic 
chemicals. The central part of the overview will present photosensitivity, photoaging, sun-
induced carcinogenesis, reactions to heat and cold and skin problems caused by chemical and 
physical agents as they stand as the most widespread groups of conditions. The analysis of 
each of the groups of conditions will encompass the most common diseases followed by their 
clinical presentations, treatments and potential prevention.  
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1. Introduction 
 
Skin is the largest organ in the body and it is one of crucial interfaces between man and his 
environment. Unfortunately, the human race has begun to redefine its surrounding which has 
caused for new dangers for the skin. Through the constant interaction with the environment 
skin is affected by the external factors more than any other organ. Growing exposure to 
industrial products, UV radiation and other factors are only a few examples of current 
environmental insults that the skin has to endure. Beside the given physical surrounding the 
skin is also affected by factors such as stress, drugs or chemicals. Having that said, a 
comprehensive investigations of the above mentioned factors are being undertaken- 
consequently leading to ever more important progress in understanding, treating and 
preventing those harmful effects. The relation between skin and the environment stands as a 
challenging topic of research. The thorough research is a basis to comprehend the 
pathogenesis, the development of the diseases and invention of preventive measures and 
innovative treatments. A combination of genetics and the above mentioned environmental 
factors influence the process of photoaging, carcinogenesis and development of other 
diseases. For the last decades people are becoming more aware of the influence of the 
environment to their general health and especially to their skin. The ever increasing number of 
skin cancer and other conditions linked to UV exposure comes as a strong indicator of the 
importance of prevention and not just treatment options. The creators of national and 
international Health Policies are putting more and more efforts in developing campaigns so to 
increase awareness of people to protect themselves from those harmful environmental factors. 
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2. Photosensitivity 
 
Photosensitivityis an increased sensitivity or abnormal response of the skin to sunlight or 
artificial light. In particular, both UVA radiation (longer wavelengths) and UVB radiation 
(shorter wavelengths) have been observed to trigger unusual reactions of the skin in people 
with certain disorders or those who are taking particular medications. The most common 
manifestation of an increased photosensitivity is the appearance of lesions of various shapes 
and sizes on areas of the skin that have been exposed to sunlight. The time required for such a 
response to occur can be anywhere from under 30 minutes of exposure to sunlight to hours 
spent in it
1
. After having defined photosensitivity, the subsequent sections will deal with some 
of the most common diseases related to photosensitivity and photosensitivity induced by 
different drugs. 
2.1.Diseases related to photosensitivity 
 
Photosensitive dermatoses are cutaneous diseases that are caused or aggravated by sunlight 
exposure, both extrinsic factors (e.g., drugs) and intrinsic factors (e.g., inherited diseases, 
metabolic disorders) may be involved
2
. This part will give an overview of different diseases 
from the very common sunburn to a rare condition called Xeroderma Pigmentosum. 
2.1.1. Sunburn 
 
Also called UV erythema, primarily due to UVB, which reaches the earth's surface in 
abundance is one of the most common reactions to sunlight. Such erythema becomes visible 2 
to 6 hours following exposure and reaches a maximum at 24 to 72 hours. The erythema then 
typically fades over 3 to 5 days and is followed by increased skin pigmentation (tanning) in 
most individuals. After intense exposure, the erythema may be associated with blistering, 
similar to that of a second-degree thermal burn. Large amounts of UVA also reach the earth's 
surface, but it has little or no role in this process because the dose required to produce 
erythema in human skin is 100 to 1000 times greater than that contained in natural sunlight. 
However, high-intensity artificial UVA sources encountered in tanning booths can induce 
erythema and melanogenesis. Erythema can occasionally be caused by UVC, generally in 
laboratory workers exposed to germicidal lightning
3
. 
Treatments that have the theoretical potential to alter the sunburn reaction, such as 
corticosteroids andNSAIDs, have not been shown to have a clinically important impact. 
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AlthoughNSAIDs appear to have a slightly greater effect thancorticosteroids when used at 
optimal anti-inflammatory dosage, almost all of the studies initiated therapy immediately after 
or before UVB exposure, which does not replicate the clinical situation in which these agents 
would be used. In addition, the adverse effects that patients may experience with these agents 
should be considered, especially with the oral administration of high doses of NSAIDs for a 
self-limited condition. Combination therapy with topical corticosteroids and NSAIDs also 
does not appear to have clinical usefulness for patients presenting with symptomatic sunburn 
due to the pre-erythema administration schedules employed for NSAIDs and steroid 
preparations in clinical studies, and a clinical effect that is limited to the earliest phase of the 
cutaneous UV injury response
4.Nonblistering sunburn reactions can also be treated topically 
with bland emollients such as hydrated petrolatum and blistering sunburn reactions should be 
treated as second-degree thermalburns with topical silver sulfadiazine cream. Sunburn is more 
easily prevented than treated
3
. Recommendations and prevention will be discussed later on in 
the photoaging section. 
2.1.2. Solar urticaria 
 
Solar urticaria is a rare disorder that produces a rapid and abnormal response to UV radiation. 
Upon being exposed to sunlight the skin wheals as it becomes red, swollen, and will often itch 
or burn. After exposure to the sun for only five to ten minutes a rash can appear, but will 
normally subside within a few hours, provided that further exposure to sunlight is avoided. 
All areas of the skin are susceptible, yet the most commonly affected parts are those that are 
normally covered by clothing but have been exposed to light. In particular, skin that has been 
bruised is most vulnerable. Besides for swollen skin and erythema (skin that is red and 
inflamed), patients suffering from solar urticaria sometimes experience headaches, nausea, 
difficulty breathing, faintness and syncope. These additional reactions are due to a loss of 
fluid from the cells that have caused swelling. This is most common when the area of the skin 
infected by a rash is widespread. The disorder is more common in females than males and 
often appears for the first time when the patient is between 20 and 40 years old, although 
cases have been reported at much younger ages. The disorder has been observed in some 
patients to remain for many years after its onset, but in others it enters into remission or 
decreases in severity as the patient ages
5
. 
Solar urticaria is generally diagnosed from the recurring eruptions caused by exposure to 
sunlight or to artificial light. However, wheals may be produced or aggravated by light 
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shielding in some cases; certain wavelengths in the light are thought to inhibit wheals. In 
young patients, differential diagnosis from erythropoieticprotoporphyria may be necessary
2
. 
Regarding the treatment, as soon as a patient is shielded from sun exposure the rash begins to 
disappear spontaneously within several minutes to a few hours. The rash clears away 
completely without leaving a mark. Patients with solar urticaria must take measures to avoid 
or minimise sun exposure by following sun protection strategies. Oral antihistamines may be 
helpful in reducing weals and minimising pruritus but they rarely prevent the reaction 
altogether. For patients that react severely and are unable to manage their condition through 
preventative measures, phototherapy and/or photochemotherapy may be considered. These 
treatments desensitise the patient to UV radiation and are often performed prior to the summer 
months. Unfortunately desensitisation is often short-lived and repeat therapy is needed
6
.  
2.1.3. Polymorphic light eruption 
Polymorphous light eruption (PMLE) is an acquired disease and is the most common of the 
idiopathic photodermatoses. PMLE is characterized by recurrent, abnormal, delayed reactions 
to sunlight, ranging from erythematous papules, papulovesicles, and plaques to erythema 
multiforme –like lesions on sunlight-exposed surfaces. Within any 1 patient, only 1 clinical 
form is consistently manifested
7
.Polymorphous light eruption tends to manifest in the 
spring.In addition, PMLE is a recurrent condition and patients state they have had the eruption 
before and that it went away as time passed. Sunlight is clearly the primary etiologic factor for 
PMLE. The eruption of PMLE typically occurs in spring or, rarely, in winter following 
ultraviolet radiation exposure reflected from snow. Typically, the lesions of PMLE first erupt 
at the onset of a vacation in a sunny place or at a high altitude and disappear by the time the 
patient returns home. The eruption decreases in severity as the summer progresses. The onset 
of the disease is sudden. The accompanying rash is pruritic and, in some instances, painful. 
Thirty minutes to several hours of exposure are required to trigger the eruption. Sun-exposed 
skin, especially that normally covered in winter (eg, upper chest, arms), is primarily affected, 
but autosensitization may lead to a generalized involvement. Most patients have associated 
pruritus, but some patients describe stinging and pain
8
.  
In polymorphous light eruption (PMLE), laboratory tests are generally performed to rule out 
other dermatoses, such as erythropoietic protoporphyria or lupus erythematosus. Antinuclear 
antibody (ANA), anti-Ro, and anti-La tests, as well as urine, stool, and blood porphyrin 
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levels, should be obtained9.Avoidance of sunlight is important, and the patient should wear 
protective clothing(i.e., hats and long-sleeved shirts) when outdoors on sunny days. 
Sunscreening preparationsare sometimes helpful. Other treatment is directed to the 
underlying cause, where possible. Polymorphous eruptions manifested as papules, plaques, or 
dermatitis may respond to topical corticosteroids. In patients with polymorphous 
photosensitivity or cutaneous LE, prolonged (2 to 4 mo) administration of 
hydroxychloroquine 200 to 400 mg/day orally often reduces or completely suppresses 
photosensitivity and may be tried if treatment is required and sunscreens are not effective. 
Potential eye toxicity should be watched for by an ophthalmologist particularly by examining 
visual fields. PUVA (psoralens plus UVA) is also effective in preventing some cases of 
polymorphous light eruptions if used before sun exposure but should not be used in LE
7
. 
 
2.1.4. Chronic actinic dermatitis 
 
Chronic actinic dermatitis (CAD) is a photosensitivity disorder in which outbreaks of 
eczematous rashes develop most often on exposed skin. Patients suffering from the disorder 
often suffer form papules, or inflamed bumps, and plaques, which are scaly, raised patches of 
skin. These rashes often itch and are appear red in color. Nearly 90% of those suffering from 
CAD are males, and of these most are elderly. Chronic actinic dermatitis refers to a number of 
related disorders, including persistent light reactivity, actinic reticuloid, photosensitive 
eczema, and photosensitivity dermatitis. The progression from one of these disorders to CAD 
is characterized by transition from a photoallergic contact dermatitis to a persistent 
photosensitivity. It has been observed that, although the disorder can last all year long, its 
outbreaks become most severe during the summer months when the body is exposed to the 
greatest amount of UV radiation. The rashes are usually found on the backs of hands, scalps, 
face, and upper chest. In more extreme cases patients will have intense eruptions of papules 
and plaques on exposed areas of skin adjacent to other areas that are exposed yet remain 
healthy
5
. 
Patients with chronic actinic dermatitis must take measures to avoid sun exposure by 
following sun protection strategies. In severe cases it may be necessary to admit the patient to 
a dark room in hospital. In addition, if a contact allergy in involved the patient must try to 
avoid the offending substance. Treatment also includes:emollients, topical corticosteroids, 
topical tacrolimus or pimecrolimus cream. In severe cases, oral immune suppressive 
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treatments may be required. These include: systemic corticosteroids, azathioprine, ciclosporin. 
Extremely cautious desensitizing with photochemotherapy or narrowband UVB with systemic 
steroid cover has been successful in some cases. The condition may spontaneously resolve, 
sometimes many years after the onset of the disease. For most people it is a lifelong condition 
that requires significant lifestyle changes to avoid sunlight as well as contact allergens
10
.  
2.1.5. Xeroderma pigmentosum 
 
Patients with xeroderma pigmentosum (XP) have a congenital failure in repairing and 
eliminating DNA that is damaged by UV exposure. The failure results in severe 
photosensitive symptoms. UV causes a replication fork bypass of a pyrimidine 
(thyminethymine) dimer. XP is classified by unscheduled DNA synthesis, a classification 
index, into 8 subtypes: groups A to G, and a variant group. Group A is the severest, and the 
variant group is the mildest. In the variant group, UDS is normal; however, there is failure in 
DNA modification after synthesis. All groups are autosomal recessive and occur in 1 person 
out of 100,000 to 1.5 persons out of 100,000. About 30% of patients with XP are born from 
consanguineous marriages. The main genes responsible for XP have been identified. 
Abnormalities are not found at birth; however, intense and delayed sunburn in 1- to 2-month-
old infants may be recognized as the onset of XP group A. Extremely intense and persistent 
sunburn recurs on sun-exposed sites such as the face and dorsa of hands and forearms. As 
sunburn recurs, the skin dries and coarsens, presenting an unwashed appearance with 
ephelides-like pigmented patches, exfoliation, hypopigmented macules and telangiectasia. 
Seborrheic keratosis, small tumors, and ulcers occur in succession at the base of these lesions 
in childhood. Basal cell carcinoma, squamous cell carcinoma, keratoacanthomaand malignant 
melanoma occur subsequently. 
Sunlight should be thoroughly avoided by limiting outings in daytime, wearing clothes that 
cover the body thoroughly, keeping the hair long, wearing UV-screening eyeglasses, sticking 
UVscreening film on windows, applying shades to fluorescent lamps, and applying sunscreen. 
Early detection and treatment of cutaneous malignant tumor are important
2
.  
 
2.2.Drug-induced photosensitivity 
 
Drug-induced photosensitivity refers to the development of cutaneous disease as a result of 
the combined effects of a chemical and light. Exposure to either the chemical or the light 
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alone is not sufficient to induce the disease; however, when photoactivation of the chemical 
occurs, one or more cutaneous manifestations may arise. These include phototoxic and 
photoallergic reactions, a planus lichenoides reaction, pseudoporphyria, and subacute 
cutaneous lupus erythematosus. Photosensitivity reactions may result from systemic 
medications and topically applied compounds. Wavelengths within the UV-A (320-400 nm) 
range and, for certain compounds, within the visible range, are more likely to cause drug-
induced photosensitivity reactions, although occasionally UV-B (290-320 nm) can also be 
responsible for such effects. UV-B wavelengths are most efficient at causing sunburn and 
nonmelanoma skin cancer. In patients who present with photosensitivity, it is often difficult to 
differentiate phototoxic from photoallergic reactions. However, they have a number of 
distinguishing characteristics. Phototoxic reactions occur because of the damaging effects of 
light-activated compounds on cell membranes and, in some instances, DNA. They develop in 
most individuals if they are exposed to sufficient amounts of light and drug. Typically, they 
appear as an exaggerated sunburn response and often occur within minutes or hours of light 
exposure. By contrast, photoallergic reactions are cell-mediated immune responses to a light-
activated compound. Photoallergic reactions resemble allergic contact dermatitis, with a 
distribution limited to sun-exposed areas of the body. However, when the reactions are severe 
or prolonged, they may extend into covered areas of skin. Photoallergic reactions develop in 
only a minority of individuals exposed to the compound and light; they are less prevalent than 
phototoxic skin reactions. The amount of drug required to elicit photoallergic reactions is 
considerably smaller than that required for phototoxic reactions. Moreover, photoallergic 
reactions are a form of cell-mediated immunity; their onset often is delayed by as long as 24-
72 hours after exposure to the drug and light
11
. The mainstays of treatment of drug-induced 
photosensitivity include identification and avoidance of the causative agent, the use of sun 
protection, and the institution of measures for symptomatic relief.Topical corticosteroids and 
cool compresses may alleviate drug-induced photosensitivity. The use of systemic 
corticosteroids should be reserved for the most severe cases. If sunscreens are not the cause of 
the photosensitivity, they should be used liberally. The sun protection factor (SPF) may not be 
a reliable indicator of protection against drug-induced photosensitivity. The SPF refers to the 
degree of protection against sunlight-induced sunburn, primarily that caused by UV-B. Most 
drug-induced photosensitivity reactions are caused by wavelengths within the UV-A range. 
Therefore, sunscreens that absorb UV-A should be prescribed. Sunscreens that contain 
avobenzone, titanium dioxide, and zinc oxide are more effective in blocking out UV-A 
radiation than sunscreens that contain other ingredients
12
.  
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2.2.1. Antibiotics 
 
Amongst antibiotics, the 3 following classes of drugs are involved in photosensitivity: 
tetracyclines, sulfonamides and fluoroquinolones. Although the mechanism that causes the 
medication to become phototoxic is unclear, it appears to be oxygen-dependent and can result 
in altered cell membranes and DNA. With all those 3 classes of antibiotics, a higher dosage 
often results in a greater sensitivity to UV radiation. It is of crucial importance that patients 
who are on those medications make an active attempt to defend their skin from the dangers of 
the sun's rays. The most effective behaviors for doing this include avoiding direct exposure to 
sunlight (glass does not block UVA rays from penetration), application of a broad spectrum, 
high SPF (30+) sunscreen, and wearing protective clothing including a wide-brimmed hat, 
pants, and long sleeves
5
. 
2.2.2. Non-Steroidal Anti-Inflammatory Drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are medications used regularly in the 
treatment of arthritis and intermittently for fever, pain and headache. They are most 
commonly used systemically, usually as an oral formulation but can also be used as a 
suppository or administered by intramuscular injection. Topical gels and creams containing 
NSAIDs may be applied to sports injuries, painful joints and, most recently, for the treatment 
of solar (actinic) keratoses (sun spots). Common non-specific skin reactions to NSAIDs are:  
 Exanthema 
 Fixed drug eruption – especially phenazone derivatives  
 Itch  
 Morbilliform rash (maculopapular)  
 Photosensitivity – both phototoxic (propionate derivatives) and photoallergic  
 Urticaria (hives) and angioedema  
The use of topical NSAIDs gels or creams to treat pain has been reported to cause a 
photocontact dermatitis. Most commonly this has occurred with ketoprofen gel with an 
incidence of 0.013-0.028/1000. Often the reaction appears after stopping the application when 
the skin is next exposed to sunlight. Therefore it is usually reported in summer. The reaction 
commonly extends beyond the area where the gel had been applied. The reaction can be 
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severe, requiring hospital admission in some cases. Testing has shown this to be a 
photoallergic contact dermatitis, crossreacting with other NSAIDs including tiaprofenic acid, 
fenofibrate, oxybenzone and benzophenone. Bufexamac has also been reported to cause 
contact dermatitis
13,14
.  
2.2.3. Retinoids 
 
Vitamin A and other retinoids reduce abnormal growth and development of keratinocytes 
within the pilosebaceous unit. Reversal of the hypercornification within the follicular canal, as 
well as the induction of accelerated proliferation of the follicular epithelium helps to 'unplug' 
the follicle
15
. This in turn inhibits development of the microcomedo and noninflammatory 
lesions, resulting in fewer anaerobic conditions, a reduction in P. acnes growth and a 
microenvironment less favorable for the development of inflammation. In addition, the newer 
retinoids reduce the rupture of comedones into the surrounding skin, also resulting in less 
inflammation
16,17
. All topical retinoids can produce irritant dermatitis, but this is less 
problematic with second- and third-generation agents and with cream formulations rather than 
gels
18
. Patients should be warned that they may experience an initial flare of inflammatory 
lesions at the start of treatment
19
. These adverse effects can be minimized by starting at lower 
concentrations for a short period with incremental increases in contact time and preparation 
strength. Owing to potential photosensitivity, topical retinoids are best applied at night and 
patients should not expose themselves to excessive UV light
20
. 
 
2.2.4. Cosmetics/Fragances 
 
Phototoxicity or photoirritation is a chemically induced nonimmunologic acute skin irritation 
requiring light (usually within the UVA spectrum, ie, 320-400 nm). The skin response 
resembles exaggerated sunburn and does not require prior sensitization; it can be caused by a 
single simultaneous exposure to the chemical and light source. The photoactive chemical may 
enter the skin via topical administration, or via ingestion, inhalation, or parenteral 
administration. The reaction can be evoked in all subjects as long as the concentration of the 
chemical and the dose of light are sufficient
21
. 
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Photosensitivity eruptions affect the exposed areas. Most often, these are the following sites.  
 Face: sparing behind ears, under nose, eyelids, hairline (make-up may be protective)  
 Neck: sparing the anterior portion under the chin and including a V on the anterior 
chest  
 Dorsum of hands: sparing finger webs  
 Forearms: sharp cut-off at cuff level  
 Feet: dorsum of feet, sparing strap marks from sandals  
In general an irritant or toxic reaction is sunburn-like and results in deep pigmentation; an 
allergic reaction is more likely to resemble acute or chronic dermatitis. However, as both 
types of reaction may arise from the same substances, repeated or chronic eruptions are best 
distinguished by patch testing. Exposing duplicate sets of patches to UVA is known as 
photopatch testing. It is non-standardised but allergen sets are available. The most frequent 
photoirritants and photoallergens found in cosmetics are: Psoralens, fragances and sunscreens 
(less frequent today as lower concentrations used and PABA is avoided). 
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3. Photoaging 
 
Skin aging is a multisystem degenerative process that involves the skin and skin 
support system. Young faces tend to be convex with full lips, sweeping jaw line with full 
temples and cheeks. Aged face tends to be concave with flat lips, sunken temples and cheeks, 
scalloped mandible and more shadows. Aging caused by the genes we inherit and depending 
on the passage of time per se is called chronological or intrinsic aging. Intrinsic akin aging is 
characterized by atrophy of the skin with loss of elasticity and slowed metabolic activity. The 
signs of intrinsic aging are fine wrinkles, thin and transparent skin, loss of underlying fat, 
facial bone loss, dry skin, inability to sweat sufficiently to cool the skin, hair loss and 
unwanted hair. The other type of aging is known as extrinsic aging and is caused by 
environmental factors. Among harmful environmental factors that contribute to extrinsic 
aging, long-term effects of repeated exposure to ultraviolet light are most significant 
and are referred to as photoaging. It is a cumulative process and depends primarily on the 
degree of sun exposure and skin pigment. UV irradiation invokes a complex sequence of 
specific molecular responses that cause damage to the skin connective tissue. Photoaging 
affects the sun-exposed areas and is characterized clinically by fine and coarse 
wrinkling,roughness, dryness, laxity, telangiectasias, loss of tensile strength and pigmentary 
changes. There is also an increase in development of benign and malignant neoplasms on 
photoaged skin
22
. 
 
3.1.Histological and clinical characteristics of photoaged skin 
 
Photoaged skin is characterized by coarse wrinkles, loss ofelasticity, pigmented spots, 
dryness, verrucous papules, and telangiectasia. The age at onset and expression of these 
photoaged characteristics appear to differ between racial phenotypes or pigmentary groups
23
. 
It is commonly held that lighter skinned people tend to manifest photoaging by wrinkles, 
whereas Asian ethnicities exhibit pigmented spots (solar lentigines) rather than wrinkles. The 
severity of photoaging in any case depends on cumulative sun exposure, and is usually most 
determined by occupation and life-style
24
. Histopathologically, aged skin undergoes 
progressive disorientation of dermal collagen and elastic fiber bundles
25,26
. In photoaged skin, 
there can be a significant increase in space between fiber bundles, thinning of fibers and 
increased disorganization of fiber proteins.Intrinsic and photoaged skin shows an age-
dependent reduction of cutaneous microvasculature, leading to decreased skin temperature 
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and decreased nutritional supply which possibly may cause thinning of nail plates and skin
27
. 
It is reported that there are age-dependent decreases in the cutaneous vascularity of both sun-
exposed facial and sun-protected buttock skin, but the alteration is more prominent in 
photoaged skin
28
. In intrinsically aged skin, there is no significant difference in the 
vascular density, although there is a decrease in vessel size between aged and young skin
29
. 
However, the papillary dermis of photoaged facial skin of elder donors showed apparent 
decreases in vessel size, vascular number, compared with that of younger skin. Acutely, UV 
exposure stimulates angiogenesis through vascular endothelial growth factor (VEGF) 
upregulation via MEK-ERK activation and thrombospondim-1 downregulation via P13K-Akt 
activation in human epidermis, although with chronic exposure blood vessels may be 
decreased in UV-damaged skin
30
. Among non-fibrous components in dermis and epidermis, 
hyaluronan plays an essential role in supporting tissue architecture, and is also involved in cell 
migration and differentiation during inflammation
31
. Further, HA is known as one of the 
important factors to protect skin from dryness by its capacity to bind water. An age-dependent 
decrease in hyaluronan content has been reported
32
. In addition, the rate of UVB-induced HA 
synthesis 24 h after UVB irradiation is also decreased in aged 
human skin compared to young skin
33
.HA metabolism in human skin is rapidly and 
differentiallyregulated by acute UVB irradiation. HA content in epidermis anddermis 
decreases 3h after a single UVB exposure due to increaseddegradation and decreased 
synthesis of HA. In epidermis, new HAincreases by 24 h after UV irradiation, but remains 
lower in thedermis. In dermis, HA degradation products increase for 24 h-post irradiation, 
suggesting that balance between HA synthesis and degradation determines HA recovery in 
tissue after UV irradiation
34
. 
 
 
 
3.2.Intrinsic and extrinsic aging 
 
Intrinsic aging, also known as the natural aging process, is a continuous process that normally 
begins in the mid-twenties. Within the skin, collagen production slows down and elastin has a 
bit less spring. Dead skin cells do not shed as quickly and turnover of new skin cells may 
decrease slightly. While these changes usually begin in the twenties, the signs of intrinsic 
aging are typically not visible for decades. The signs of intrinsic aging are fine wrinkles, thin 
and transparent skin, loss of underlying fat, bones shrink away from the skin due to bone loss, 
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which causes sagging skin, dry skin, inability to sweat sufficiently to cool the skin, graying 
hair, hair loss and unwanted hair
35
..Young faces tend to be convex with full lips, sweeping 
jaw line and full temples and cheeks. Aged face tends to be concave with flat lips, sunken 
temples and cheeks, scalloped mandible and more shadows
36
. The skin support system 
includes the bone, cartilage, and subcutaneous compartments, which provide the architectural 
support for the dermis, epidermis and stratum corneum. A multipronged approach to aging 
involves reversing the undesirable changes in each of these structures. One of the most 
important areas for consideration is the bony architecture over which theskin lies. Without a 
strong framework, the skin hangs formless over the face. Bone demineralization begins 
at around 25 and leads to dulling of the facial features. Bone replacement therapy, such as 
bisphosphonates, is usually not initiated until overt evidence of osteoporosis is present. The 
architecture of the cartilage of the face with bones defines the shape of the face. The most 
important facial structure dependent on cartilage is the nose. The cartilage does not disappear 
with advancing age, but does change in shape. The change occurs during pregnancy due to 
relaxins that are secreted at high levels during the final trimester
37
. The subcutaneous 
compartment undergoes much of the change that contributes to the aged appearance 
of the face. In intrinsic aging, there is a decreased fat cell size, diminished fat cell function, 
impaired fat cell differentiation and redistribution of fat cells. Subcutaneous fat from all over 
the body is removed and lost, including facial fat, and redeposited intra-abdominally, 
probably to lower growth hormone levels
38
. The face shows excess concavity with prominent 
muscles and bony landmarks as the result of lipoatrophy
36
. Fat redistribution in the body 
occurs with menopause
39,40
. In postmenopausal women, fat is typically redistributed to the 
breast, arms, waist, thighs and buttock with loss of facial fat. Volume loss begins to occur 
under the eyes in the tear troughs, as well as in the cheek area. Volume loss becomes evident 
around the nasolabial folds due to the loss of volume in the cheek and perioral area. 
Prominence of the nasolabial fold is a major change associated with midface aging. This fold 
has a dynamic stage in earlier life and a static appearance with aging. Viable epidermis and 
dermis are the essence of the skin. Structural destruction and loss of dermal collagen fiber 
bundles lead to wrinkling and increased appearance of muscular attachments. Irregular 
melanization leads to lentigines, poikiloderma, and melasma and prominent telangiectasias 
lead to erythema
41
. With aging, the loss of extracellular matrix andits major component 
hyaluronate, which stabilizes the intracellular structures by forming viscoelastic network in 
which collagen and elastin fibers are embedded, induces loss of the skin mechanical 
functions. Hyaluronate provides a cushion effect to the skin structures including the 
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epidermis. Solidity of the skin is provided by the extracellular matrix and the loss of 
hyaluronate and consequently of the viscoelastic buffering system would contribute to easy 
tearing resulting in skin lacerations
42
. The treatable stratum corneum problem that leads to 
fine wrinkling is dehydration. The corneocytes and intercellular lipids can be restored to their 
normal brick-and-mortar lamellar organization
37
. 
 
A number of extrinsic or external factors often act together with the normal aging process to 
prematurely age our skin. External factors that prematurely age the skin are repetitive facial 
expressions, sun, gravity, sleeping positions, and smoking. Repetitive facial movements 
actually lead to fine lines and wrinkles. When we use a facial muscle, a groove forms beneath 
the surface of the skin, which is why we see lines to form with each facial expression. As skin 
ages and loses its elasticity, the skin stops springing back to its line-free state, and these 
grooves become permanently etched on the face as fine lines and wrinkles. Changes related to 
gravity become more pronounced with aging. When the skin elasticity declines in middle age, 
the effects of gravity become evident. Gravity causes the tip of the nose to droop, the ears to 
elongate, the eyelids to fall, the jowls to form, and the upper lip to disappear while the lower 
lip becomes more pronounced. Resting your face in the same way every night for years 
eventually also leads to wrinkles. Sleep wrinkles become etched on the surface of the skin and 
no longer disappear. Cigarette smoking causes biochemical changes in the body that 
accelerate aging. People who smoke for a number of years tend to develop an unhealthy 
yellowish hue and deeply wrinkled, leathery skin not seen in non-smokers. These signs can be 
greatly diminished by stopping smoking
43,35
. Most premature aging is caused by sun 
exposure. 
Unlike chronological aging, which depends on the passage of time per se, photoaging depends 
primarily on the degree of sun exposure and skin pigment. Individuals who have outdoor 
lifestyles, live in sunny climates and are lightly pigmented will experience the greatest degree 
of photoaging
44
. Among harmful environmental factors that contribute to extrinsic aging, 
long-term effects of repeated exposure to UV radiation are most significant and are referred to 
as photoaging. Photoaging is directly correlated to the quantity of UV rays received during 
the course of lifetime. The effects of photodamage are often evident many years before 
intrinsic aging is apparent. Young people who are exposed to a great amount of UV rays 
appear prematurely aged. 
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3.3.Prevention and treatment 
 
Chronically sun-exposed skin is characterized by pigmentedspots (lentigos), deep wrinkles 
(so-called leathery skin) and verrucous papules, superimposed on chronologically degenerated 
skin, This structural and functional change is termed photoaging. There are essentially three 
strategies to prevent photoaging: (1) prevention of UV penetration into skin, (2) inhibition of 
inflammation by anti-oxidants and anti-inflammatory molecules, (3) medically based 
rejuvenation treatments of photoaged skin
45
. 
 
3.3.1. Prevention of UV penetration by sunscreens 
 
The primary approach to preventing photoaging is by sunavoidance and by the proper use of 
sunscreen, appropriate clothing, and hats. Adopting a healthy attitude about sun exposure can 
prevent the unwelcome signs of aging such as wrinkles and lentigos as well as non-melanoma 
skin cancer. When out-ofdoors, this would imply that shade seeking behavior would prevail. 
Proper daily use of protective materials against solar ultraviolet radiation (UVR) should 
prevent both acute and chronic damage of the skin. Sunscreen use is generally accepted to 
reduce the level of DNA damage and protect sun-exposed skin from erythema, suggesting a 
protective role against UVR-induced photoaging and skin carcinogenesis
46,47
.Exposure to 
UVA is ofparticular concern because the UVA energy reaching the earth’s surface 90-99% of 
the total, UVA passes through glass, and only decreases by 50% in winter. Further, UVA 
radiation causes DNA damage, such as CPD and 8-OHdG and induces photoaging as 
mentioned earlier. There are two types of sunscreens, chemicals which absorb UV photons 
and physical agents which reflect or scatter UV light. Sunscreens have long been known to 
protect against UV-induced erythema, as reflected by SPF values. In the 1980’s and early 
1990’s sunscreen was expected to protect skin from UV-induced carcinogenesis48,49. In the 
past few years, however, the importance of broad-spectrum protection covering both UVB 
and UVA radiation has been recognized
50,51
. Taken together, it is recommended to use daily 
broadspectrum sunscreen that blocks both UVB and UVA radiation
52,53
. At present, a safe 
level of daily UVR exposure to the public has not been established, 
however, it can recommended that the public reduce their life-time UVR exposure to a level 
as low as possible. Many commercial sunscreens on the market are formulated to 
be broad-spectrum, and new technology has increased their photostability. 
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Modern sunscreens such as Parsol 1789 and Mexoryl SX and XL cover at least part of the 
UVA spectrum , and together with efficient UVB absorbers and reflective micro-sized 
titanium dioxide are highly effective broad-spectrum filters, often used to 
protect patients with UVA sensitivity
54
. Consumers can be advised to adjust their sunscreen to 
the environmental and activity related conditions: a broad-spectrum 
sunscreen with SPF 50 and PA +++ for outdoor activities on sunny days in summer, and a 
sunscreen with SPF 10-20, PA ++ for daily, incidental exposure. Currently, there is 
controversy over the link between low serum levels of vitamin D and the risk of cancers 
originated in several organs 
55,56
Suberythemal doses of UVB (several minutes to a 
quarter of hour exposure at noon in summer) produce vitamin D3 (Vit D3) for daily calcium 
and bone metabolism
57
. However, repeated suberythemal UVR exposures on human skin have 
beenshown to induce significant DNA damage in epidermal cells andeven sunburn erythema 
after consecutive exposures
58
. At this time, the American Academy of Dermatology 
recommends that the sun protection measures outlined above be followed and that vitamin D 
levels be maintained by dietary and supplemental vitamin D.  
 
 
 
3.3.2. Prevention of UV-induced ROS and inflammation 
 
Enzymes which convert ROS to harmless water and molecularoxygen protect skin from ROS-
induced damages. The levels of these major endogenous anti-oxidant enzymes, superoxide 
dismutase, catalase, glutathione peroxidase, and glutathione reductase are shown to decrease 
after a single and repeated exposurse to UVB radiation in mice and pig 
59,60
and also in aged 
and photoaged skin of human 
60
. The level of catalase in epidermis is much higher than in the 
dermis, and decreases after a single UVB and UVA exposure, recovering 3-4 weeks after 
exposure. Topical and oral administration of biologically relevant 
antioxidants, such as vitamin E, vitamin C, coenzyme Q, polyphenols and carotenoids have 
minimal evidence that they provide photoprotection and reduce acute photodamage in human 
skin
61,62
. Recently, we found that CoQ10 suppresses UV induced MMP1 production of 
fibroblasts by inhibiting the production of cytokines in KC. We speculate that anti-oxidative 
activity of CoQ10 may inhibit the production of inflammatory cytokines in UV irradiated 
KCs
63
. Several polyphenolic antioxidants of plant, such as green tea, grape seed, pomegranate 
19 
 
and others, have been shown to be effective in vitro for prevention of cellular photodamage, 
and green tea extract has been shown to reduce photoaging and skin cancer
64,65
. Resveratrol 
derived from grape skin is a novel agent for anti-aging and anti-photoaging 
treatment of the skin, possibly through its antioxidant properties and through regulation of 
energy metabolism in mitochondria and epidermal cell differentiation
66,67
. 
Topical retinoids have been demonstrated to inhibit UV-induced inflammation mediated by 
AP-1 and NFkB transcription factors
68,69
. All-trans-retinoic acid (ATRA) prevents UV-
induced accumulation of c-Jun protein, resulting the suppression of AP-1 
binding to MMPs gene. Further, ATRA is shown to stimulate the breakdown of jun protein 
through uliquitin-proteasome degradation. 
In conclusion, we recommend the use of sunscreen from childhood to prevent acute severe 
sunburn and to reduce the levelof accumulated DNA damage caused by daily repeated 
exposures, and to both retard the onset of visible photoaging, and reduce the 
risk for melanoma and non-melanoma skin cancer
45
. 
 
 
 
3.3.3. Treatment and rejuvenation of photoaged skin 
 
Retinoids are one of the most commonly used topical agents toreverse the signs of 
photoaging. Topical use of ATRA for several months proved to reduce wrinkle numbers, 
length and depth by increasing fiber components in dermis and make epidermis thick. A new 
retinoic acid agonist, N-retinoyl-D-glucosamine has been shown to be effective on photoaged 
skin without the irritation commonly seen in ATRA treatment. Further ATRA and its 
derivatives are shown to reduce melanin pigment such as mottled hyperpigmentation, freckles 
and solar lentigines by topical use possibly by increased turnover rate of epidermis. To treat 
acute inflammation, topical immune suppressant, tacrolimus, nonsteroidal 
anti inflammatory drugs (NSAIDs) and corticosteroid hormone are extremely effective. 
Recent advances in non-ablative laser and light therapy of pigmented skin and wrinkles have 
made it possible to treat photo-damaged skin effectively and safely. Noninvasive cosmetic 
procedures are now popular worldwide, since they are effective, and relatively painless and 
safe compared to deep chemical peels more common decades ago. Chemical peeling by 
salicylic acid in polyethylene glycol can be used to treat photodamaged skin and has been 
shown to suppress skin tumor development in irradiated hairless mice. Pigmented lesions are 
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commonly treated by laser, IPL (intensepulsed light), superficial chemical peel and topical 
application of whitening agents, cosmetics and drugs. Further, a highly effective drug delivery 
system, electroporation, is also available for whitening and wrinkle care. In many cases, 
patients are treated by combined use of these modalities, depending on the disease and skin 
conditions. Chemical peels are effective for both superficial wrinkle amelioration and for 
whitening ofpigmented spots. Glycolic acid and salicylic acid (macrogole) are popular in 
Japan. These acid formulations essentially dissolve the upper layer of skin, whereas 
trichloroacetic acid can be used for lower dermal layer (medium depth peel). Laser 
resurfacing is a technique used where the molecular bonds of the skin cells are dissolved by a 
laser. It is used for the treatment of wrinkles, solar lentigenes, sun damage, scars, 
actinickeratosis and telangiectasias or ―spider veins‖. Laser treatment is based on the theory 
that selective removal of skin tissue triggers a wound-healing response, remodeling of 
collagen fibers, dermal matrix, and rebuilts epidermal components. For discoloration, Qswitch 
ruby laser is commonly used, particularly is useful for the treatment of melanin pigment 
located in dermis. IPL is also veryeffective to reduce and often erase epidermal pigment in 
solar lentigines and freckles by killing keratinocytes containing melanin. Complete 
resurfacing was first done with a CO2 laser. More commonly now, laser resurfacing is done 
with a fractional laser. The term fractional pertains to the method in which the laser light is 
transferred. Tiny pinpoints of laser light are used to deliver the laser to the surface of the skin 
in only a fraction of the area. Several hundred or thousands of pinpoints may be used per 
square inch, leaving healthy skin in between the ablated areas. This is intended to allow more 
rapid healing and less risk. Radiofrequency devices delivers energy by waves in the range of 
radio signals and aims to destroy the upper and some of the lower skin layers, leading to 
contraction and tightening of the skin. This has been associated with a high degree of pain and 
inflammation. Topically applied botanical extracts and synthetic molecules have been in 
widespread use for centuries in the case of the former and more recently in the case of the 
latter to rejuvenate photoaged skin 
45
. 
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4. Sunlight-induced carcinogenesis 
 
Chronic repeated exposures to sunlight fromchildhood are epidemiologically shown to be the 
main cause of skin cancers. Ultraviolet B radiation, a minor component of sunlight reaching 
tothe earth surface, is experimentally demonstratedto be the most effective light to induce skin 
cancer and can cause DNA damage, particularlycyclobutane pyrimidine dimers (CPDs) and 
(6_/4) photoproducts which induce mutation in the epidermal cells, leading to the 
development of cancer cells. UVB is also known to upregulate gene expression through 
intracellular signal transduction pathways, which may contribute to developing skin cancer at 
the tumor promotion stage. In addition, UVB is proved to suppress immune reaction, and to 
induce tolerance to antigens, which had been applied topically or systemically inexperimental 
animals. These three effects of UVBon the skin are understood to cooperativelycontribute to 
producing skin cancer in humans.Ultraviolet light A (UVA) and UVB radiationare proved to 
produce DNA damage directly andindirectly through oxidative stress. Further, reactiveoxygen 
species (ROS) are shown to activatetranscription factors, such as AP-1 and NFkB, which may 
contribute to cell proliferation and/or apoptotic cell death
70
.  
 
4.1.Non-melanocytic skin cancer 
 
There are three histological types of non-melanocytic skin cancers: basal cell carcinoma, 
squamous cell carcinoma and rare soft tissue sarcomas involving the skin, subcutaneous 
tissue, sweat glands, sebaceous glands and hair follicles
71
.Non-melanocytic skin cancer has 
long been regarded as one of the harmful effects of solar ultraviolet (UV) radiation on human 
health. The epidemiologic evidence that sun exposure causes skin cancer is mainly indirect. 
Incidence or mortality is inversely related to latitude in populations of mainly European origin 
(e.g., the United States, Australia), and is higher in people born in Australia (high ambient 
solar radiation) than in migrants to Australia from the United Kingdom (lower ambient 
radiation). Skin cancer occurs mainly at sun-exposed body sites and in people who are 
sensitive to the sun; a reduced capacity to repair UV-induced DNA damage appears to 
increase the risk. The direct evidence linking sun exposure and skin cancer is weaker with few 
well-conducted studies of sun exposure in individuals. Mostly, studies of total sun exposure 
have not found statistically significant positive associations; those that did, had not adjusted 
for potential confounding by age and gender and thus their interpretation is limited. Studies of 
occupational sun exposure had relative risks not greater than 2.0; recreational exposure has 
22 
 
been little studied. Other measurements, less direct but potentially less prone to measurement 
error, are sunburn (not evidently associated with skin cancer risk) and indicators of benign 
cutaneous sun-damage (strongly associated but lacking empirical evidence that sun exposure 
is their main cause)
72
. 
 
4.1.1. Basal cell carcinoma 
 
Basal cell carcinoma (BCC) is a nonmelanocytic skin cancer (ie, an epithelial tumor) that 
arises from basal cells (ie, small, round cells found in the lower layer of the epidermis). BCC 
accounts for 80% of all skin cancers but is the least likely cancer to behave in a malignant 
fashion and metastasize. BCC differs from squamous cell carcinoma, which accounts for 16% 
of skin cancers and is more life threatening. Although BCC is observed in people of all races 
and skin types, dark-skinned individuals are rarely affected, and it is most often found in 
light-skinned individuals (type 1 or type 2 skin). Those with type 1 skin are very fair and have 
red or blond hair and freckles; these individuals always burn and never tan. Those with type 2 
skin are fair and burn easily while tanning minimally. Whites of Celtic ancestry have the 
highest risk for BCC. Incidence is low in blacks, Asians, and Hispanics
73
.Although the exact 
etiology of BCC is unknown, a well-established relationship exists between BCC and the 
pilosebaceous unit, as tumors are most often discovered on hair-bearing areas. Many believe 
that BCCs arise from pluripotential cells in the basal layer of the epidermis or follicular 
structures. These cells form continuously during life and can form hair, sebaceous glands, and 
apocrine glands. Tumors usually arise from the epidermis and occasionally arise from the 
outer root sheath of a hair follicle, specifically from hair follicle stem cells residing just below 
the sebaceous gland duct in an area called the bulge
74
. Sunlight, particularly chronic exposure, 
is the most frequent association with development of BCC; risk correlates with the amount 
and nature of accumulated exposure, especially during childhood. Patient geographic location 
affects the risk of developing skin cancer. A latency period of 20-50 years is typical between 
the time of ultraviolet (UV) damage and BCC clinical onset. Radiation exposure that 
contributes to BCC development may include tanning booths and UV light therapy. Both 
short-wavelength UVB radiation (290-320 nm, sunburn rays) and longer wavelength UVA 
radiation (320-400 nm, tanning rays) contribute to the formation of BCC. UVB is believed to 
play a greater role in the development of BCC than UVA, however, and is the primary agent 
responsible for most skin cancer
75
.UVB and UVC can modify unsaturated chemical bonds of 
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nucleic acids, which may lead to mutations. UVC does not penetrate the atmospheric ozone 
layer. The UVA spectrum is absorbed by melanin and, through free-radical transfer, affects 
cellular deoxyribonucleic acid (DNA). Mutations caused by UV radiation typically include 
cytosine (C) to thymine (T), or CC to TT, translocation. This process can cause activation of 
oncogenes or inactivation of tumor suppressor genes, leading to tumor initiation and 
progression
76
.The skin can repair superficial damage, but the underlying cumulative damage 
remains, including DNA damage. The damage worsens with each successive sun exposure, 
causing a lifetime progression
77
. 
Basal cell carcinoma occurs mostly on the face, head (scalp included), neck, and hands
78
.It 
rarely develops on the palms and soles. BCC usually appears as a flat, firm, pale area that is 
small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following 
minor injury. BCCs may have one or more visible and irregular blood vessels, an ulcerative 
area in the center that often is pigmented, and black-blue or brown areas. Large BCCs may 
have oozing or crusted areas. The lesion grows slowly, is not painful, and does not itch. 
Younger patients (< 40 y) may have a lower prevalence of BCC on the head and neck and a 
higher prevalence on the trunk, with greater tendency to superficial BCC, than in older 
patients
79
.Childhood BCC is exceedingly rare in the absence of other underlying conditions. 
Only 107 cases of de novo childhood BCC have been reported in the literature, but the 
majority (90%) occurred on the head and neck, and aggressive subtypes were observed in 
20% of the total cases
80
. 
Characteristic features of BCC tumors include the following: 
 Waxy papules with central depression 
 Pearly appearance 
 Erosion or ulceration, often central 
 Bleeding, especially when traumatized 
 Crusting 
 Rolled (raised) border 
 Translucency 
 Telangiectases over the surface 
 Slow growing (0.5 cm in 1-2 y) 
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Clinical presentation of BCC varies by type. Physical examination of the skin aids in 
determination of tumor extent, subtype, and involvement of important cosmetic and functional 
structures. Matted BCCs may indicate deeper tumor invasion and involvement of deeper 
underlying structures. In patients with recurrent or deeply infiltrative tumors, involvement of 
the facial nerve or branches of the trigeminal nerve should be investigated. Facial nerve 
function can be monitored by comparing facial symmetry during voluntary facial movements 
with that at rest. Sensory nerve function can be tested and compared to the nonaffected side 
by means of light touch and pinprick. Orbital invasion can cause diplopia, proptosis, and 
ophthalmoplegia. Any limitation in ocular movements and/or diplopia should be tested.  BCC 
seldom causes regional or distant metastasis, with the exception of the metatypical 
basosquamous type. To evaluate for lymph node metastasis, particular attention should be 
taken to examine the parotid posterior auricular, suboccipital, and upper cervical groups of 
lymph nodes
81
.  
Several different clinicopathologic types of BCC exist, each with distinct biologic behavior: 
 Nodular - Cystic, pigmented, keratotic 
 Infiltrative 
 Micronodular 
 Morpheaform 
 Superficial 
According to the 2011 National Comprehensive Cancer Network Clinical Practice Guidelines 
in Oncology: Basal Cell and Squamous Cell Skin Cancers, the goal of treatment is elimination 
of the tumor with maximal preservation of function and physical appearance. As such, 
treatment decisions should be individualized according to the patient's particular risk factors 
and preferences
82
.In nearly all cases, the recommended treatment modality for basal cell 
carcinoma is surgery
83,84
.Treatments vary according to cancer size, depth, and location. 
Dermatologists may perform nearly all of the therapeutic options in an outpatient setting. 
Most therapies are well established and widely applied; nevertheless, researchers are studying 
some additional options (eg, photodynamic therapy with photosensitizers)
85,86,87
 and awaiting 
further reports. Local therapy with chemotherapeutic and immune-modulating agents is useful 
in some cases of BCC. In particular, small and superficial BCC may respond to these 
compounds. Topical 5% imiquimod is approved by the US Food and Drug Administration 
(FDA) for the treatment of nonfacial superficial BCCs that are less than 2 cm in diameter. 
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Lesions are generally treated once daily, 5 days per week, for a duration of 6-12 weeks. 
Likewise, topical fluorouracil is approved by the FDA for the treatment of superficial BCC, 
administered twice daily for 3-6 weeks
88
.Although no formal restrictions on fluorouracil have 
been determined based on lesion size or location, it is most commonly used on smaller 
superficial BCC on the trunk and extremities. Both imiquimod and fluorouracil may be used 
topically for prophylaxis or maintenance in patients who are prone to having many BCCs. For 
tumors that are more difficult to treat (ie, infiltrative BCC, morpheaform [sclerosing] BCC, 
micronodular BCC, and recurrent BCC) or those in which sparing normal (noncancerous) 
tissue is paramount, Mohs micrographic surgery should be considered and discussed with the 
patient. For metastatic BCC, the 2011 NCCN guideline recommends clinical trials of systemic 
chemotherapy, particularly platinum-based combination therapy, which has been observed to 
produce useful, even complete, responses in a few patients. Clinical trials of investigational 
biologic modifiers such as hedgehog pathway inhibitors are also recommended.
82 
Regarding the prevention, avoid possible potentiating factors (eg, sun exposure, ionizing 
radiation, arsenic ingestion, tanning beds). The regular use of sun-protecting clothing (eg, 
wide-brimmed hat, long-sleeved shirts, sunglasses with ultraviolet [UV] protection) is 
recommended when outdoors. Instruct patients to avoid sun exposure particularly during the 
middle of the day (ie, 11:00 am to 3:00 pm), which is the most dangerous time. Also, the sun's 
rays are especially intense in sunny climates and at high altitudes, and UV radiation can also 
pass through clouds and water. Patients should be instructed to be careful on the beach and in 
the snow because sand, water, and snow reflect sunlight and increase the amount of received 
UV radiation. Researchers are investigating chemoprevention with systemic administration of 
retinoids as cancer preventive agents in patients at high risk for developing basal cell 
carcinoma; the efficacy of these agents will take several years to evaluate, however, the 
American Cancer Society recommends a dermatologic examination every 3 years for people 
aged 20-40 years and every year for people older than 40 years
89
. 
 
4.1.2. Cutaneous squamous cell carcinoma 
 
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, after 
basal cell carcinomas. Although cSCC is not often fatal, many of these lesions occur in the 
head and neck region, where surgery for advanced-stage disease can be disfiguring
90
. 
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Malignant transformation of normal epidermal keratinocytes is the hallmark of cSCC. One 
critical pathogenic event is the development of apoptotic resistance through functional loss of 
TP53, a well-studied tumor suppressor gene. TP53 mutations are seen in over 90% of skin 
cancers diagnosed in the United States, as well as in most precursor skin lesions, suggesting 
that loss of TP53 is an early event in the development of cSCC
91
.Exposure to cancer-
promoting stressors and the response of the body to those exposures (host response) promote 
the development of cSCC. Well-known risk factors include the following:  
 UVR exposure 
 Immunosuppression 
 Exposure to ionizing radiation or chemical carcinogens 
 Human papillomavirus (HPV) infection 
Chronic UVR exposure, such as through tanning beds, medical UV treatments, or cumulative 
lifetime sun exposure, is the most important risk factor for the development of cSCC. UVR is 
a known mutagen capable of inducing DNA damage that can lead to keratinocyte 
transformation. UVR has also been shown to alter the cutaneous immune response, leaving 
the skin susceptible to tumor formation
92
. 
Approximately 70% of all cSCCs occur on the head and neck, most frequently involving the 
lower lip, external ear and periauricular region, or forehead and scalp. Consequently, the head 
and neck should be of particular interest in a comprehensive examination of a patient with 
suspected cSCC. The following features of the lesion should be noted: 
 Location (eg, eyelid SCC is more common on the lower eyelid) 
 Size 
 Character (eg, smooth/nodular, vascularity, color): SCC may appear as plaques or 
nodules with variable degrees of scale, crust, or ulceration  
 Presence of ulcerationA 35-year-old man with human immunodeficiency virus (HIV) 
infection presented with a 2-year history of a slowly enlarging, left lower eyelid 
lesion; incisional biopsy revealed squamous cell carcinoma. A large, ulcerated, 
invasive squamous cell carcinoma of the left lower eyelid. This patient also had 
perineural invasion of the infraorbital nerve extending into the cranial base.  
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Frequently, the presentation of cSCC is preceded by the presence of actinic keratoses. These 
precancerous lesions appear as scaly plaques or papules, often with an erythematous base. An 
actinic keratosis is usually only several millimeters in size and ranges from normal skin color 
to pink or brown. Patients with multiple actinic keratoses have an estimated 6-10% lifetime 
risk of developing skin cancer. The overall appearance of any skin lesion must be detailed. 
The classic presentation of a cSCC is that of a shallow ulcer with heaped-up edges, often 
covered by a plaque. Of course, the presenting appearance of each cSCC varies according to 
the site and extent of disease
93
.  
Low-risk cutaneous squamous cell carcinoma (cSCC) on the trunk and extremities can be 
treated with electrodessication and curettage. For invasive cSCC, surgical excision and Mohs 
micrographic surgery are the primary treatment options; with appropriate patient selection, 
these techniques have comparable cure rates. Radiation therapy is typically used as an 
adjuvant to surgery, to provide improved locoregional control, but it may be used as primary 
therapy in patients who are unable to undergo surgical excision. Chemotherapy may be 
considered as adjuvant therapy in select highest-risk cases of cSCC. In particular, emerging 
evidence suggests that epidermal growth factor receptor (EGFR) inhibitors may be useful 
adjuncts to surgical treatment. Systemic chemotherapy may be considered for metastatic 
cSCC.  
Prevention is an important aspect of managing cSCC. Given the central role that ultraviolet 
radiation (UVR) plays in the pathogenesis of cSCC, methods aimed at decreasing UVR 
exposure form the cornerstone of cSCC prevention. Several effective treatment modalities 
exist for precancerous skin lesions, including carcinoma in situ and actinic keratosis. Most of 
these treatments are easily performed in an outpatient setting
94
. Regarding the global 
prevention against cSCC, those methods used for the prevention of the BCC again prevail: 
sunsreens, mechanical protection (clothing) and regular visits at the dermatologist for skin 
cancer screening. 
 
4.2.Melanoma 
 
Melanoma is a tumor that develops as a result of the malignant transformation of 
melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the 
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skin but can arise in other locations where neural crest cells migrate, such as in the 
gastrointestinal tract or brain. Melanoma predominantly affects adults, with a peak incidence 
in the fourth decade, and has no sex prevalence. A patient's risk of developing a second 
primary melanoma after diagnosis of the first one is 3-5%. Melanoma poses an increasingly 
difficult problem as more people are affected. The incidence is estimated to be rising by 
almost 6% per year. Recognition of this disease as an entity is crucial so that people may seek 
medical attention while the tumor is still in its early stages, prior to metastasis. Efforts should 
be directed toward public awareness campaigns
95
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4.2.1. Frequency and risk factors 
 
In the United States, the incidence of melanoma continues to increase, with the prevalence of 
trunk and extremity lesions rising relatively faster than that of head and neck lesions; 
however, survival rates are improving. An estimated 34,100 people developed melanoma in 
the United States in 1995, with 7,200 deaths. This is an increase from the 27,600 new cases in 
1990 and the 6,300 deaths. Furthermore, approximately 44,200 new melanoma diagnoses 
were made in 1999, and approximately 7,300 deaths were reported. An estimated 62,480 new 
cases of melanoma will occur in the United States in 2008, with 8,420 deaths.Currently, in the 
United States, approximately 1 in 50 white persons, 1 in 1,000 black persons, and 1 in 200 
Hispanic persons develops melanoma at some point in his or her lifetime.Internationally, 
incidence varies worldwide. White populations in Australia, New Zealand, South Africa, and 
the southern United States have the highest rates, while Asian populations in Hong Kong, 
Singapore, China, India, and Japan have the lowest rates. This suggests that white persons 
who live in sunny areas are at significant risk.  
- Etiology/risk factors: 
 Family history - Positive family history in 5-10% of patients; with at least one affected 
relative, 2.2-fold higher risk 
 Personal characteristics - Blue eyes, fair and/or red hair, pale complexion; skin 
reaction to sunlight (easily sunburned); freckling; benign and/or dysplastic 
melanocytic nevi (number has better correlation than size); immunosuppressive states 
(transplantation patients, hematologic malignancies)  
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 Sun exposure over lifetime - High UVB and UVA radiation exposure (Recent 
evidence has shown that the risk of melanoma is higher in people who use sunscreen. 
Because sunscreen mostly blocks UVB, people using sunscreen may be exposed to 
UVA more than the general public, provided those people are exposed to the sun more 
than the general public; low latitude; number of blistering sunburns; use of tanning 
beds. 
 Atypical mole syndrome (formerly termed B-K mole syndrome, dysplastic nevus 
syndrome, familial atypical multiple mole melanoma) - Over 10 years, 10.7% risk of 
melanoma (vs 0.62% of controls); higher risk of melanoma depending on number of 
family members affected (nearly 100% risk if 2 or more relatives have dysplastic nevi 
and melanoma)  
 Socioeconomic status - Lower socioeconomic status may be linked to more advanced 
disease at the time of detection. One survey of newly-diagnosed patients found that 
low SES-individuals have decreased melanoma risk perception and knowledge of the 
disease 
95
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4.2.2. Histologic classification 
 
Melanomas are classified into 4 major types based on growth pattern. They are superficial 
spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous 
melanoma. Other more unusual types include mucosal lentiginous melanoma, desmoplastic 
melanoma, and verrucous melanoma.  
- Superficial spreading melanoma 
Superficial spreading melanomas constitute approximately 70% of melanomas. 
Histologically, the characteristic cells can be present singly or in nests along the dermal-
epidermal junction, but they also may migrate into the stratum granulosum or stratum 
corneum. These cells can invade the papillary dermis with an inflammatory lymphocytic 
infiltrate.  
Clinically, they usually arise in a preexisting dysplastic nevus.Typically, this lesion changes 
slowly over several months to years. They are usually flat but may become irregular and 
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elevated in later stages. The lesions average 2 cm in diameter with variegated colors and 
peripheral notches, indentations, or both.  
- Nodular melanoma 
Histology of nodular melanomas is characterized by extensive vertical growth into the dermis 
with a minimal radial component. They comprise approximately 15-30% of melanoma 
diagnoses. These tumors typically are blue-black but may lack pigment in some 
circumstances. They are known to arise without a preexisting lesion.  
- Lentigo maligna melanoma 
Lentigo maligna melanomas represent 4-10% of melanomas. On a cellular level, dermal and 
epidermal changes from sun exposure must be present. The histologic appearance is one of 
irregularly shaped hyperchromatic cells that form spindle-shaped nests. The epidermis is 
atrophic, while the dermis contains solar elastosis with chronic inflammatory infiltrates. From 
a clinical standpoint, lentigo maligna melanomas are often larger than 3 cm, flat, tan, and 
begin as small, frecklelike lesions (see image below). They occur in sun-exposed areas (eg, 
face and neck of older individuals). Marked notching of the borders is present. Lentigo 
maligna melanoma usually arises within a Hutchinson freckle (lentigo maligna). When tumor 
thickness and location are taken into consideration, the prognosis for these melanomas is not 
believed to be worse than that for other subtypes. 
- Acral lentiginous melanoma 
This tumor comprises 2-8% of melanomas in whites and 35-60% of melanomas in dark-
skinned people. Cellular proliferation is present along the dermal-epidermal junction with 
microinvasion into the papillary dermis. The cells have increased melanin granule production, 
which fills their dendritic extensions. Acral lentiginous melanomas occur on the palms of the 
hands, beneath the nail beds, and on the soles of the feet. They may appear on the palms and 
soles as flat, tan, or brown stains with irregular borders. Subungual lesions can be brown or 
black, with ulcerations in later stages. No correlation with a worse prognosis is demonstrated 
for these lesions when tumor thickness is considered.  
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- Desmoplastic melanoma 
These lesions account for approximately 1% of melanoma cases; they are fairly rare. They 
demonstrate a tendency for perineural invasion, especially in the head and neck. They have a 
propensity for higher local recurrence rates but lower regional metastasis rates
96
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4.2.3. Clinical presentation, classification and staging 
 
Patients usually present with skin lesions that have changed in size, color, contour, or 
configuration. The acronym "ABCDE" is the hallmark of international public awareness 
campaigns and may be used to remember the physical characteristics suggestive of 
malignancy. ABCDE stands for asymmetry, irregular border, color variations (especially red, 
white, and blue tones in a brown or black lesion), diameter greater than 6 mm, and elevated 
surface. Lesions may itch, bleed, ulcerate, or develop satellites. See images below for 
examples. Perform excisional biopsy on these suggestive lesions so that a pathologist can 
confirm the diagnosis. Shave biopsies and electrodesiccation are inadequate; a full thickness 
of skin is essential for proper histologic diagnosis and classification. The most important 
prognostic indicator for stage I and II tumors is thickness; obtain a full-thickness biopsy 
specimen for adequate pathologic interpretation. Biopsy results ultimately determine the 
margins of resection and which patients are candidates for sentinel lymph node biopsy and 
other adjuvant treatment. 
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Two classification schemes have been developed, based on either the vertical thickness of the 
lesion in millimeters or the anatomic level of invasion of the layers of skin. The Breslow 
classification scheme is used almost exclusively now because it more accurately predicts 
future tumor behavior. The Clark level is now used only in the staging of thin (T1) 
melanomas. The TNM (tumor, node, metastasis) system is used for clinical staging as 
designated by the American Joint Committee on Cancer (AJCC) staging system
97
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4.2.4. Treatment and prognosis 
 
 Stage 0: Widely excise the tumor or previous biopsy site; use a 0.5- to 1-cm margin 
for melanomas in situ. The 5-year relative survival rate is 97%. 
 Stage I: 1-cm excision margins are adequate, but lesions greater than 1 mm require 2-
cm margins; for lesions with a depth greater than 1 mm, many authorities recommend 
sentinel lymph node biopsy at the time of wide local excision. The 5-year survival rate 
is 90-95%. If a sentinel node biopsy yields findings of melanoma in the lymph nodes, 
the 5-year survival is approximately 75%.  
 Stage II: Perform a 2-cm surgical resection; carry out a complete therapeutic 
lymphadenectomy on patients with suspected lymph node metastases based on 
physical examination findings; consider sentinel lymph node biopsy if no clinically 
positive nodes are present. The 5-year relative survival rate is from 85 to 45%. 
 Stage III: Wide local excision of the primary tumor with 2-cm margins remains first-
line therapy;perform regional lymph node dissection because a stage III melanoma 
represents nodal disease; If the nodal status is unknown, consider a sentinel lymph 
node biopsy to determine if the disease is stage I, II, or III. The 5-year survival rate is 
approximately 45%. It is higher if the melanoma has spread to only one node and is 
lower if it has spread to more than 3. It is higher if the spread can only be seen under 
the microscope. It is lower if the melanoma was ulcerated.  
 Stage IV: Usually refractory to standard therapy; thus, consider these patients for 
clinical trials; surgical resection of isolated metastases in the gastrointestinal tract, the 
brain, the lungs, or bone may be performed for palliation; metastatic lymph nodes also 
may be removed for palliation; radiation may provide symptomatic relief for 
metastases to bone, the brain, or viscera. Stage IV: The 5-year survival rate for stage 
IV melanoma is approximately 10%. It is higher if the spread was to skin or distant 
lymph nodes
9899
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33 
 
4.2.5. Prevention 
 
 Seek the shade, especially between 10 AM and 4 PM. 
 Do not burn. 
 Avoid tanning and UV tanning booths. 
 Cover up with clothing, including a broad-brimmed hat and UV-blocking sunglasses. 
 Use a broad spectrum (UVA/UVB) sunscreen with an SPF of 15 or higher every day. 
For extended outdoor activity, use a water-resistant, broad spectrum (UVA/UVB) 
sunscreen with an SPF of 30 or higher. 
 Apply 1 ounce (2 tablespoons) of sunscreen to your entire body 30 minutes before 
going outside. Reapply every two hours or immediately after swimming or excessive 
sweating. 
 Keep newborns out of the sun. Sunscreens should be used on babies over the age of 
six months. 
 Examine your skin head-to-toe every month. 
 See your physician every year for a professional skin exam.
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5. Reactions to heat and cold 
 
Skin interacts with the environment through exchange of radiant energy in a variety of forms. 
„Heat― and „cold― are often regarded as states of high or low kinetic energy in molecules, 
transmitted by mechanisms of conduction, convection, or infrared radiation. However, to 
understand the cutaneous interactions, we may also need to consider thermal interactions in 
the context of the broad electromagnetic spectrum. While different wavelengths do vary in 
their effects on the skin, a remarkable similarity exists in the types of cutaneous reaction 
patterns seen with many of the different wavelength categories. For example, chronic heat 
exposure, sun damage, and x-ray exposure share a common clinical appearance characterized 
by pigmentary changes, telangiectasia, and atrophy. Histologic similarities between exposure 
to UV light or to infrared radiation (heat) include proliferation of elastic fibers, increased 
cellularity of the dermis, and tortuous blood vessels. The two broad categories of reactions to 
heat and reactions to cold can be further subdivided into normal reactions that occur in all 
individuals who receive adequate exposure (e.g., burns, or erythema ab igne), and abnormal 
reactions, defined as syndromes that are only seen in certain patients (e.g., Raynaud's 
phenomenon). 
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5.1.Acute heat injury 
 
Results from exposure to extreme heat. „Extreme― is defined by factors such as the type of 
heat source, tempereature of exposure, and duration of exposure. The minimal temperature at 
which a burn can occur is 44°C. With increasing temperatures, shorter times are required, so 
that epidermal necrosis will occur in 45 minutes at 47°C or in 1 second at 70°C. 
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5.1.1. Thermal burns 
 
Burn wounds can be classified into 6 separate groups based on the mechanism of injury: 
scalds, contact burns, fire, chemical, electrical, and radiation.  Scald burn injuries can be 
caused by liquids, grease, or steam. Liquid scalds can be further divided into spill and 
immersion scalds. Fire burn injuries can be divided into flash and flame burns. The 
mechanism of burn injury can be used as a predictor of outcome. For example, patients with 
flame burns and electrical burn injuries often require hospitalization. In contrast, most patients 
with burns caused either by contact with hot surfaces or sun exposure are managed as 
outpatients. Serious burn injuries occur most commonly in males (67%). The highest 
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incidence of serious burn injury occurs in young adults (20-29 y) followed by children 
younger than 9 years. Individuals older than 50 years sustain the fewest number of serious 
burn injuries (2.3%). Major causes of severe burn injury are flame burns (37%) and liquid 
scalds (24%). For children younger than 2 years, liquid scalds and hot surface burns account 
for nearly all serious burn injuries. After age 2 years, flame burn is the most common cause of 
serious burn injuries, accounting for nearly one third of all serious burns. In much older 
persons (80 y and older), hot surface exposure is a major cause (22%) of serious burns.
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Severity of burn injury is related to the rate at which heat is transferred from the heating agent 
to the skin. Rate of heat transfer depends on the heat capacity of the agent, temperature of the 
agent, duration of contact with the agent, transfer coefficient, and specific heat and 
conductivity of the local tissues.  
 Heat capacity: Capacity of a material to hold heat energy is determined by both the 
specific heat and the heat capacity of the material.  
 Specific heat of a material: This is defined as the ratio of the amount of heat required 
to raise a specific mass of the material 1 degree in temperature, to the amount of heat 
required to raise an equal mass of a reference substance (usually water) 1 degree in 
temperature.  
 Heat capacity: This refers to a quantity of heat a material contains when it comes in 
contact with skin. Quantity of heat stored depends on the specific heat of the material 
and the amount and temperature of the material.  
The importance of heat capacity as a determinant of severity of burn injury is best illustrated 
by comparing the amount of heat stored in 10 g of 2 different materials (copper and water) 
heated to the same temperature (100°C). Specific heat of water is 4.2178 W xsec/g xK (watt 
times seconds of heat per gram mass times degrees Kelvin). If these 2 materials come in 
contact with skin, they give up their heat by cooling while skin accepts the heat by increasing 
its temperature. If the temperature of each material decreases by 60°C, water gives up 2530 W 
xsec of heat, whereas copper transfers only 230 W xsec of heat. Even if the initial 
temperatures of the 2 materials are identical, heat available from water is much more likely to 
produce a severe injury. The specific heat of water (most common cause of scald burns) is the 
highest of all the gases, metals, and solids tested to date, with the exception of ammonia and 
ether. 
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During the first day after burn injury, 3 concentric zones of tissue injury characterize a full-
thickness burn: zones of coagulation, stasis, and hyperemia.The central zone of coagulation 
has the most intimate contact with the heat source. It consists of dead or dying cells as a result 
of coagulation necrosis and absent blood flow. It usually appears white or charred. The 
intermediate zone of stasis usually is red and may blanch on pressure, appearing to have an 
intact circulation; however, after 24 hours, circulation through its superficial vessels often has 
ceased. Petechial hemorrhages may be present. By the third day, the intermediate zone of 
stasis becomes white because its superficial dermis is avascular and necrotic. The outer zone 
of hyperemia is a red zone that blanches on pressure, indicating that it has intact circulation. 
By the fourth day, this zone has a deeper red color. Healing is present by the seventh day. 
Transformation of the zone of stasis to coagulation occurs and has been related to many 
factors, including progressive dermal ischemia. Experimental studies have implicated 
prostaglandins, histamine, and bradykinin as the chemical mediators of this progressive 
vascular occlusion. They can produce edema by altering endothelial cell and basement 
membrane function to enhance permeability. When this ischemia persists, the zone of stasis 
eventually becomes a full-thickness burn injury. 
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The treatment obviously greatly depends of the extent of the wound but general principles still 
apply: cleansing of the wound with a surfactant (poloxamer 188),  removal of blisters, cover 
with a topical antimicrobial dressing. Topical antibiotics decrease microbial growth and 
reduce invasive infection. Use of prophylactic systemic antibiotics is not recommanded since 
they do not prevent wound sepsis, although they may be indicated when cellulitis is evident in 
surrounding unbured tissue. 
 
5.1.2. Erythema ab igne 
 
Erythema ab igne is a reticulate hypermelanosis with erythema resulting from repeated heat 
exposure that induces injury to the epidermis and superficial vascular plexus. The exposure, 
which need not be of long duration, results in cutaneous hyperthermia in the range of 43-
47°C. Erythema ab igne results in histopathologic changes similar to those seen in solar-
damaged skin. Although the pathogenic mechanisms in erythema ab igne are poorly 
understood, one study has shown that moderate heat acts synergistically with ultraviolet 
radiation to denature DNA in squamous cells in vitro. 
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5.2.Abnormal reactions to heat 
 
Include non-physiological phenomena like: cholinergic urticaria and erythromelalgia. 
 
5.2.1. Cholinergic urticaria 
 
Cholinergic urticaria is one of the physical urticarias brought on by a physical stimulus. 
Although this stimulus might be considered to be heat, the actual precipitating cause is 
sweating. The definition and diagnostic testing of cholinergic urticaria has been the subject of 
consensus panel recommendations
104
. Cholinergic urticaria appears rather rapidly, usually 
within a few minutes after the onset of sweating, and lasts from a half hour to an hour or 
more, with a mean duration of about 80 minutes. Cholinergic urticaria symptoms are 
sufficiently uncomfortable to cause many patients to change their patterns of activity to 
prevent attacks. Exercise is the most common precipitating event for cholinergic urticaria, but 
any stimulus that causes sweating, including elevated environmental temperature, hot food, 
sauna baths, immersion in hot water, gustatory stimuli, emotional stress, and hemodialysis,can 
bring on an urticarial attack in some persons. Exercise and hot baths exacerbate pruritus and 
provoke lesions in previously unaffected areas. Often in cholinergic urticaria, itching, 
burning, tingling, warmth, or irritation precedes the onset of numerous small (1-4mm in 
diameter), pruritic wheals with large, surrounding flares. Chilergic urticaria may appear 
anywhere on the body, except on the palms or the soles and rarely in the axillae. Sometimes, 
flares are the only presentation. 
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Sometimes, an attack of cholinergic urticaria can be aborted by rapid cooling. Ultraviolet 
(UV) light has been beneficial in some patients with the condition, but one must be 
circumspect about contraindications to UV light. Rapid desensitization with autologous sweat 
has been reported in patients resistant to conventional therapy who have sweat 
hypersensitivity. In evaluating any response to therapy, one must always consider that 
cholinergic urticaria can clear spontaneously. 
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5.2.2. Erythromelalgia 
 
Erythromelalgia is a rare disorder that is characterized by burning pain and warmth and 
redness of the extremities. There is some confusion in the literature regarding nomenclature 
and classification; however, in general, a distinction is made between primary (idiopathic) and 
secondary erythromelalgia (most commonly associated with myeloproliferative disorders), as 
well as between early- and late-onset disease. The first insights into the pathophysiology of 
erythromelalgia associated with thrombocythemia were gained when skin biopsy samples 
revealed arteriolar fibrosis and occlusion with platelet thrombi
107
. In this setting, platelets may 
have abnormal hyperaggregability. Platelet kinetic studies show decreased platelet survival, 
predominantly due to consumption. Prostaglandins and cyclooxygenase apparently play an 
important pathogenetic role. 
Causes of erythromelalgia include the following: 
 Myeloproliferative disorders 
 Idiopathic origin 
 Medications 
 Infection 
 Other associated disorders 
 Genetic mutation 
 Mushroom poisoning 
 
The classic description of erythromelalgia is a triad of redness, pain, and warmth in the 
extremities, brought on by warming or dependency and relieved by cooling (see the image 
below). Episodes may last minutes to days. They often begin with an itching sensation, 
progressing to a more severe pain with a burning quality. Pain may be so intense that the 
patient cannot walk; some must even keep their feet immersed in ice water. The lower 
extremities are affected more often than the upper extremities. The soles of feet and toes are 
most commonly involved. Involvement as high as the knees is observed but is rare. 
Involvement is usually bilateral, though not necessarily symmetric.
108
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Evaluation and treatment can be conducted in an outpatient setting. Treatment is primarily 
medical and supportive. Local measures, such as cooling or elevating the extremity, may 
relieve symptoms. Avoid excessive warming or dependency of the extremity. The 
environment should be modified so that it is not too hot. In patients with myeloproliferative 
disorders, chemotherapy to reduce the platelet count often alleviates symptoms, but it is not 
universally effective. Some patients with polycythemia vera have responded to 
phlebotomy.
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5.3.Reaction to cold– frostbite 
 
Frostbite, the most common type of freezing injury, is defined as the freezing and crystalizing 
of fluids in the interstitial and cellular spaces as a consequence of prolonged exposure to 
freezing temperatures
110
. Frostbite is a completely preventable injury that can occur with or 
without hypothermia. Below –10°C, any tissue that feels numb for more than a few minutes 
may become frostbitten. Progressive symptoms of frostbitten areas are as follows: 
 Coldness 
 Stinging, burning, and throbbing 
 Numbness followed by complete loss of sensation (This history of anesthesia suggests 
a frostbite injury.) 
 Loss of fine muscle dexterity (ie, clumsiness of fingers) 
 Loss of large muscle dexterity (ie, difficulty ambulating) 
 Severe joint pain 
Numbness over the affected area is the initial symptom of frostbite. After rewarming, severe 
throbbing and hyperemia begin and may last for weeks. Many patients complain of 
paresthesias. Long-term symptoms include cold sensitivity, sensory loss, and hyperhidrosis.
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The goal of frostbite treatment is to salvage as much tissue as possible, to achieve maximal 
return of function, and to prevent complications.If treating personnel are unfamiliar with the 
management of frostbite and its sequelae, transfer of the patient to another facility should be 
considered. The management of frostbite itself may be divided into 3 phases: field 
management, rewarming, and postrewarming management.On admission, rapidly rewarm the 
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affected area in circulating water (ie, a whirlpool bath) at 40-42°C. The circulation of water 
allows a constant temperature to be applied to the affected area. Warming is continued for 15-
30 minutes or until thawing is, by clinical assessment, complete (ie, when the distal area of 
the extremity is flushed, soft, and pliable). Avoid inadvertent slow rewarming or overheating. 
Encourage active gentle motion of the frostbitten area during the rewarming. Constantly 
monitor water temperature to ensure it does not exceed 43.3°C. Thawing takes about 20-40 
minutes for superficial injuries and as long as 1 hour for deep injuries. The most common 
error in this stage of treatment is premature termination of the rewarming process because of 
reperfusion pain. Mechanical trauma (massaging or rubbing with ice or by hand) and 
rewarming at higher temperatures and for longer periods of time are detrimental to preserving 
viable tissue and should be avoided. Direct dry heating using fire or a heater can lead to burns 
secondary to loss of temperature sensation and so should be avoided. 
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5.4.Abnormal reactions to cold 
 
In the following part, the abnormal reactions to cold are going to be described. The most 
common ones are Raynaud's phenomenon and pernio. 
 
5.4.1. Pernio 
 
Pernio or also called chilblainis due to an abnormal vascular response to cold exposure and is 
most frequent when damp or humid conditions coincide. Minor trauma also may predispose 
the acral parts to symptomatic pernio lesions in otherwise appropriate weather conditions.
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Most patients with pernio present with a history of recurrent painful and/or pruritic, 
erythematous, violaceous papules or nodules on the fingers and/or toes. Most cases of pernio 
resolve within 2-3 weeks. Elicit a history of cold exposure or repeated episodes of cold 
exposure. 
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Prophylactic warming of acral areas, achieved by heat and appropriate clothing, best prevents 
pernio. Ultraviolet light, given at the beginning of the cold, damp season, has been touted as 
preventing outbreaks of pernio in prone individuals. Pathogenesis was loosely based on 
damaging the minute vessels and minimizing their ability to vasoconstrict with subsequent 
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cold exposure. However, in at least one double-blind study, ultraviolet therapy was of no 
value in prophylaxis of pernio.
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5.4.2. Raynaud's phenomenon 
 
Raynaud’s phenomenon is caused by episodic vasospasm and ischaemia of the extremities in 
response to cold or emotional stimuli, which result in a characteristic triphasic colour change 
in extremities—usually fingers or toes—from white, to blue, to red. Raynaud’s phenomenon 
may be primary, in direct response to stimuli, or secondary to an underlying condition. In 10-
20% of cases it may be the first presentation of, or may precede the onset of, a connective 
tissue disease (such as scleroderma or mixed connective tissue disease), so that underlying 
causes must be ruled out.
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Primary Raynaud phenomenon  
 Avoidance of precipitating factors and use of gloves is indicated. 
 Use calcium channel blockers, especially those that cause vasodilation. The most 
commonly used drug is nifedipine. Use the lowest dose of a long-acting preparation 
and titrate up as tolerated. If adverse effects occur, decrease dosage or use another 
agent such as nicardipine, amlodipine, or diltiazem.  
 Angiotensin receptor blockers and intravenous prostaglandins have been advocated, 
and clinical trials have indicated some benefit. The selective serotonin uptake inhibitor  
fluoxetine has also been shown effective in at least one study.  
 Therapy with antiplatelet agents has been attempted but has not been proven effective, 
and anticoagulation is not indicated. 
 The angiotensin-receptor antagonist losartan at 50 mg/d has been found effective in 
patients with primary Raynaud phenomenon and scleroderma.  
 Topical nitroglycerin (1% or 2%) has been found to help if applied locally based on a 
limited number of controlled studies. 
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Secondary Raynaud phenomenon  
 Therapy must be tailored to the underlying disorder. 
 If associated with occupational or toxic exposure, the patient should avoid the inciting 
environment. 
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 Patients with hyperviscosity syndromes and cryoglobulinemia improve with 
treatments that decrease the viscosity and improve the rheologic properties of their 
blood (eg, plasmapheresis).  
 Unfortunately, patients with autoimmune disorders and associated Raynaud 
phenomenon do not usually respond well to therapy. 
 Hepatitis B, hepatitis C, and Mycoplasma infections need to be addressed, if present. 
 In older patients with newly onset Raynaud phenomenon and no obvious underlying 
cause, malignancy must be considered. 
 Pharmacologic therapy includes calcium channel blockers and prostacyclin analogues 
and consideration of others as listed for treatment of primary Raynaud phenomenon. 
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6. Skin problems caused by chemical and physical agents 
 
In this section it will be provided with the layout of the skin problems caused by chemical and 
physical agents. As the aera is an overlaping zone between dermatology and occupational 
medicine, both are going to be taken into consideration.  
The importance of dermal exposure has increased during the last few years, mainly because of 
the reduction of respiratory exposure to toxicants. Pesticides, aromatic amines and polycyclic 
aromatic hydrocarbons are considered to be the chemicals at highest dermal risk. In the 
occupational exposure limit lists of the American Conference of Governmental Industrial 
Hygienists and of many countries, compounds that can be absorbed through the skin are 
identified by a skin notation. However, a generally accepted criterion for assigning skin 
notation does not exist. The recent attempts to develop health-based dermal occupational 
exposure limits have not been accepted, thus in practice their use has remained limited. 
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6.1.Chemical agents 
 
It is estimated that more than 13 million workers in the United States are potentially exposed 
to chemicals that can be absorbed through the skin. Dermal exposure to hazardous agents can 
result in a variety of occupational diseases and disorders, including occupational skin diseases  
and systemic toxicity.
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6.1.1. Chemical agents - overview 
 
Occupational Skin Diseases are the second most common type of occupational disease and 
can occur in several different forms including:Irritant contact dermatitis, allergic contact 
dermatitis, skin cancers, skin infections, skin injuries, and other miscellaneous skin 
diseases.Contact dermatitis is one of the most common types of occupational illness, with 
estimated annual costs exceeding $1 billion.Workers at risk of potentially harmful exposures 
of the skin include, but are not limited to, those working in the following industries and 
sectors:Food services, cosmetology, health care,agriculture, cleaning... 
Studies show that absorption of chemicals through the skin can occur without being noticed 
by the worker, and in some cases, may represent the most significant exposure pathway. 
44 
 
Many commonly used chemicals in the workplace could potentially result in systemic toxicity 
if they penetrate through the skin (i.e. pesticides, organic solvents). These chemicals enter the 
blood stream and cause health problems away from the site of entry. 
The rate of dermal absorption depends largely on the outer layer of the skin called the stratum 
corneum (SC). The SC serves an important barrier function by keeping molecules from 
passing into and out of the skin, thus protecting the lower layers of skin. The extent of 
absorption is dependent on the following factors: 
 Skin integrity (damaged vs. intact) 
 Location of exposure (thickness and water content of stratum corneum; skin 
temperature) 
 Physical and chemical properties of the hazardous substance 
 Concentration of a chemical on the skin surface 
 Duration of exposure 
 The surface area of skin exposed to a hazardous substance
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6.1.2. Contact dermatitis 
 
As mentionned before, acute and chronic contact dermatitis are responsible for about 90% of 
occupational dermatoses; most of these reactions mediated by irritant rather than allergic 
mechanisms. 
Irritant contact dermatitis (ICD) is a non-immunologic reaction that manifests as an 
inflammation of the skin caused by direct damage to the skin following exposure to a 
hazardous agent. The reaction is typically localized to the site of contact. Available data 
indicates that ICD represents approximately 80% of all cases of occupational contact 
dermatitis. ICD may be caused by phototoxic responses (e.g., tar), acute exposures to highly 
irritating substances (e.g., acids, bases, oxiding/reducing agents), or chronic cumulative 
exposures to mild irritants (e.g., water, detergents, weak cleaning agents). 
Allergic contact dermatitis (ACD) is an inflammation of the skin caused by an immunologic 
reaction triggered by dermal contact to a skin allergen. For ACD to occur, a worker must be 
first sensitized to the allergen. Subsequent exposures of the skin to the allergenic agent may 
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elicit an immunologic reaction resulting in inflammation of the skin. The reaction is not 
confined to the site of contact and may result in systemic responses. ACD may be caused by 
industrial compounds (i.e. metals, epoxy and acrylic resins, rubber additives, chemical 
intermediates), agrochemicals (i.e. pesticides and fertilizers), and commercial chemicals. 
Because the symptoms and presentation of ICD and ACD are so similar, it is extremely 
difficult to distinguish between the two forms of contact dermatitis without clinical testing 
(e.g. patch testing). The severity of contact dermatitis is highly variable and depends on many 
factors including: 
 Characteristics of the hazardous agent (irritant and/or allergen) 
 Concentration of the hazardous agent (irritant and/or allergen) 
 Duration and frequency of exposure to the hazardous agent (irritant and/or allergen) 
 Environmental factors ( e.g., temperature, humidity) 
 Condition of the skin (e.g., healthy vs. damaged skin, dry vs. wet)
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6.2.Physical agents 
 
Many physical agents in the environment and especially at the workplace can cause or 
exacerbate skin diseases. Excessive heat can lead to miliaria, erythemy ab igne and intertrigo. 
Also, sweating increases  the hazard of chemical exposures by increasing percutaneous 
absorption of certain particules or solutions. Extreme heat can lead to heat prostration or to 
burns. Workers at special risk are bakers, foundry workers... The opposite problem, being 
hypothermia can lead to frostbite and is seen in outdoors workers. Prolonged exposure to 
moisture can lead to maceration.  
Exposure to high-frequency vibrating tools such as chain saws can produce Raynaud's 
phenomenon, vasospasm, objective sensory and motor neurologic deficits, and may progress 
to gangrene. Repetitive mechanical trauma produces characteristic pathologies seen in 
occupational medicine like: calluses, knucke pads and dystrophic fingernails. Having in mind 
that minor trauma in people with preexisting dermatose may also produce lesions of psoriasis, 
lichen planus and vitiligo by the isomorphic reaction. (Koebner). 
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Occupational exposure to electromagnetic radiation is a major cause of skin disease; UVR 
causes acute erythema (sunburn) and chronic changes such as photoaging and cancer. 
Workers traditionally at risk for such effects include arc welders, faarmers, outdoor laborers 
and sailors. These effects may be seen in the future in indoor workers with the increasing use 
of artificial UVR sources in the printing and plastics industries. The role of occupational 
exposure in producing chronic solar damage can be difficult to assess since the disease may 
follow the exposure by many years and there is frequently a strong history of recreational 
exposure to sunlight as well. Phototoxicity may also occur from the combination of 
occupational light exposure and non occupational chemicals (thiazide diuretics, tetracyclines, 
nonsteroidal antiinflammatory drugs). Occupational exposure to ionizing radiation occurs 
chiefly among medical, dental, and laboratory workers and can produce characterisitc 
radiodermatitis and aggressive squamous cell cancers. Any potential hazards posed by 
exposure to microwave radiation and to video display terminals are not well defined at 
present.  Fiberglass dermatitis represents a unique type of physical irritations. Spicules of 
spun fiberglass enter the epidermis and produce intense localized pruritus, often without an 
objective primary lesion, rarely with small urticarial papules. Typically, those working with 
fiberglass develop some tolerance over the course of repeated exposures. Proper cleansing of 
skin and clothing is important lest a family epidemic occur through contamination. 
3 
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7. Conclusion 
 
There are number of conditions caused by factors inherent to the physical environment. The 
conditions vary from the common and benevolent ones- as in the case of light sunburn, to the 
aggressive forms of cancer such as melanoma. All of the conditions are triggered by factors 
that can be of chemical or physical origin, and also combination of the two. The work offered 
a thorough overview of the following conditions- photosensitivity, photoaging, sun-induced 
carcinogenesis, skin reactions to heat and cold, and skin reactions to physical and chemical 
agents. Together with the description of causes of the conditions, detailed clinical features 
were presented encompassing the treatment methods. However, in each of the condition, one 
must bear in mind the role of the early prevention. 
In the case of diseases related to photosensitivity, prevention comes as a key factor. On the 
other hand, drug-induced photosensitivity can be prevented by awareness of the prescriber of 
medicines that can come as potential triggers. Photoaging is a condition that can be 
accelerated by external factors and can be controlled through preventive methods including 
proper skin care, controlled exposure to sun, but also cosmetic procedures.Early prevention is 
also a key instrument in combating the sun-induced carcinogenesis. Public awareness and 
early detection can significantly reduce the occurrence of the melanoma or BCC. 
In the matter of skin reaction to physical and chemical agents, mostly occurring at the work 
place, proper storage and practices relating to manipulating the dangerous agents are crucial 
in prevention. 
Together with thorough researches conducted within the field which are raising the quality of 
care offered, continuous efforts in preventive policies are of utmost importance in the matter. 
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